Advanced Search
GAN Xia, NIAN Siyun, WANG Guoping. Advances in the development of farnesoid X receptor antagonists[J]. Journal of China Pharmaceutical University, 2016, 47(5): 521-530. DOI: 10.11665/j.issn.1000-5048.20160503
Citation: GAN Xia, NIAN Siyun, WANG Guoping. Advances in the development of farnesoid X receptor antagonists[J]. Journal of China Pharmaceutical University, 2016, 47(5): 521-530. DOI: 10.11665/j.issn.1000-5048.20160503

Advances in the development of farnesoid X receptor antagonists

  • Farnesoid X receptor(FXR), a member of the nuclear receptor superfamily, plays an important role on the regulating bile acid, lipid and glucose homeostasis. FXR antagonist can stimulate the conversion of total cholesterol into bile acid by improving the activity of CYP7A1. It can also reduce the content of triglyceride, low-density lipoprotein and increase that of high-density lipoprotein by regulating the relevant target genes. Considering the above facts, FXR antagonist is expected to become a potential drug to treat hyperlipidemia. In recent years, great progress has been made in the research on FXR antagonists with their various structural types having been obtained. This article introduces natural and synthetic FXR antagonists reported in recent years.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return